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Objectives: Vascular access dysfunction is the major cause of morbidity in patients on hemodialysis to treat end stage renal
disease. Preclinical studies have demonstrated that the perivascular placement of implants containing allogeneic aortic
endothelial cells (Vascugel) reduces thrombosis, inflammation, stenosis and increases lumen diameter in porcine models
of arteriovenous fistulae (AVF) and arteriovenous grafts (AVG). We conducted a phase I/II clinical study to investigate
the safety of Vascugel placement around the surgical anastomotic sites of newly constructed dialysis accesses.
Methods: From July 2006 to August 2006, eight patients (4 AVG, 4 AVF) were treated with two Vascugel sponges at the
venous anastomosis in the open–label phase I trial. From January 2007 to August 2007 57 patients (30 AVG and 27 AVF)
were randomized in a 2:1 fashion to receive eitherVascugel or controlmatrices (placebo) at surgery. The phase IIAVGpatients
had sponges placed at both the venous and arterial anastomoses. All patientswere followed for 24weeks. The primary objective
of the study was to demonstrate the safety (incidence of infection, intervention, and thrombosis) of Vascugel compared with
placebowithin 30days post-surgery. Secondary endpoints included assessments of patency, lumendiameter, and immunologic
sensitization to human leukocyte antigens (HLA) determined by measurement of panel reactive antibodies (PRA).
Results: There was no difference in early complication rates between the Vascugel and placebo groups at 4 weeks (10.9%
vs 21.1%, respectively). There were no statistically significant differences in primary or assisted primary patency between
the intent to treat groups at 24 weeks. Vascugel treated AVG had a primary patency rate of 38% and an assisted primary
patency rate of 72% (vs 23% and 58%, respectively, for placebo). Vascugel treated AVF had a primary patency rate of 60%
at 24 weeks and an assisted primary patency rate of 96% (vs 62% and 88%, respectively, for placebo). A greater than 30%
increase in PRA was detected in 9 of the 46 (19.5%) Vascugel treated patients and one of the 19 (5.2%) placebo patients
(P  .26) and was not associated with any evidence of local or systemic complications.
Conclusions: Targeted local therapy with perivascular, allogeneic endothelial cells is a safe and novel therapeutic approach
that may be ideally suited to control the response to injury at surgical anastomoses. Larger randomized trials are needed
to determine if Vascugel can prolong AVG or AVF patency. (J Vasc Surg 2009;50:1359-68.)Vascular access failure is a major complication in pa-
tients receiving hemodialysis to treat end stage renal disease
(ESRD).1,2 Graft thrombosis is the cause of 80% of all
vascular access dysfunction in expanded polytetrafluoroeth-
ylene (ePTFE) hemodialysis grafts, and in over 90% of
thrombosed arteriovenous grafts (AVG) the underlying
pathology is stenosis caused by venous neointimal hyper-
plasia at either the venous anastomotic site or in the prox-
imal vein.3 Although arteriovenous fistulae (AVF) is the
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cant limitations secondary to both early and late failures.4
Concomitant with efforts to increase the prevalence of AVF
in the hemodialysis population, there is a growing inci-
dence of nonmaturation, often resulting in prolonged use
of indwelling catheters.5 Failure to mature of AVF is a
complex issue related to many factors such as vessel size,
surgical technique, and the development of accessory
veins.6 However, both early and late fistula failure are
characterized by vascular stenosis that often occurs within
the first few centimeters of the anastomosis in approxi-
mately 20% to 40% of cases.7-9
The vascular endothelium is central to an understand-
ing of vascular biology and critical to vascular repair after
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December 20091360 Conte et alinjury. The endothelium regulates local biology by provid-
ing structural boundaries to the circulating blood while also
producing and supplying compounds that have the capacity
to regulate vascular physiology, such as heparan sulfate
(HS) and transforming growth factor-1 (TGF-1) among
many others.10-13 Upon damage to the vessels during the
placement of a new AV access, the endothelium is disrupted
and underlying smooth muscle cells (SMC) are injured.
Biomechanical and hemodynamic forces such as wall ten-
sion and shear stress are important modulators of the injury
response. These events lead to inflammation as well as
proliferation and migration of SMC, resulting in lesion
formation, constrictive remodeling, and lumen loss.14 Due
to the complexity of the mechanisms of AV access failure, it
is unlikely that a single factor aimed at any one process will
successfully treat the causes of failure. In fact, at the present
time, despite the enormity of this problem, there are no
effective pharmacologic measures for the prevention or
treatment of hemodialysis access failure.15,16
The use of endothelial cells (EC) as a cell-based therapy
to modify vascular injury has been under active investiga-
tion for some time, primarily in the form of methods to
improve luminal endothelialization of prosthetic grafts and
Fig 1. Schematic and images of sponge placement.A,D
adjacent to venous anastomosis and outflow segment in A
sponges adjacent to venous anastomosis and outflow segm
to arterial anastomosis (phase II) in AVG patients. C, I
D, Image of placement around venous anastomosis anddamaged native vessels.17,18 However, the ability of theendothelium to regulate vessel wall biology may not be
limited to a luminal location, and recent studies have sug-
gested that perivascular endothelial cell implants influence
the vessel response to injury across a spectrum of preclinical
models.19-23 In the present study, we investigated the
safety and feasibility of adventitial allogeneic endothelial
implants in a clinical setting of AV access placement.
METHODS
Study design. A single protocol was developed which
encompassed a dual study approach, treatment of AVG and
AVF. The Vascular intimal Hyperplasia: Extending Arterial
and venous patency, Limiting vascular Trauma, and inhib-
iting Hyperplasia while re-establishing vascular health (V-
HEALTH) protocol was a two-stage (phase I and II)
design within each of the surgical treatment options. An
initial limited phase I safety and feasibility trial of Vascugel
enrolled four patients in each group, AVF and AVG (total
of eight patients at three participating sites), with each
patient receiving two implants placed adjacent to the ve-
nous anastomosis (Fig 1). The phase I patients were fol-
lowed for 30 days, and their data were reviewed by an
independent data monitoring committee (DMC, Appen-
m of placement of two 1 4 0.3 cm sponges (arrows)
atients. B,Diagram of placement of two 1 4 0.3 cm
phase I and II) and one 1 4 0.3 cm sponge adjacent
of a 1  4  0.3 cm sponge used in the clinical trials.
ow vein in an AVG subject.iagra
VF p
ent (
magedix, online only), which recommended proceeding to the
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randomized, double-blind, study in patients undergoing
creation of AVG or AVF. Patients were randomized 2:1 to
receive either Vascugel or control matrices (placebo) im-
mediately prior to surgery, using a computer-generated
permuted block randomization. The proposed sample size
of 30 patients in each of the AVG and AVF groups (20
Vascugel and 10 placebo) was considered appropriate for
an exploratory phase I/II study to collect necessary infor-
mation regarding the safety and activity of the investiga-
tional product for this indication.
Study patients. The institutional review board at each
participating site approved the protocol and all study pa-
tients provided written informed consent. Individuals un-
dergoing placement of new upper extremity fistula or grafts
were eligible for enrollment in V-HEALTH if they were
currently receiving maintenance therapy of ESRD with
hemodialysis. Major exclusion criteria included patients on
an active transplant list, more than one prior access in the
target limb, chronic, systemic immunosuppressive therapy,
CBC hematocrit 24%, platelet count 100  103/L,
white blood cell count  4000/L or  12,000 L,
bleeding disorder or hypercoagulable condition, hepatitis
B, hepatitis C, HIV/AIDS, two times lab control value
of albumin, ALT (SGPT), alkaline phosphatase, AST/
(SGOT) or total bilirubin, allergy to bovine or porcine
products, allergy to collagen/gelatin products, panel reac-
tive antibodies (PRA) 30%, pregnant, and current IV
drug use. Patients also underwent preoperative vein map-
ping to identify blood vessels in the upper extremities that
were suitable for AVG or AVF creation.
Investigational product. Vascugel is being developed
as a novel cell therapy product for use following vascular
access surgery and is composed of allogeneic aortic EC
cultured in a gelatin (Gelfoam; Pfizer, New York, NY)
matrix. The human EC, isolated from the aorta of single
cadaver donors, are obtained from Lonza (Walkersville,
Md) and tested extensively for endothelial cell purity; bio-
logical function (assays for secretion of HS, TGF-1 and
fibroblast growth factor, uptake of acetylated LDL as well
the ability to inhibit cultured SMC proliferation), the pres-
ence of bacteria, fungi, known human pathogens, and
other adventitious agents according to FDA proposed
rules.24,25 The cells are cryopreserved for later expansion
and formulation in gelatin sponges. Vascugel was supplied
to the clinical sites as sponges having dimensions of 1.0 
4.0  0.3 cm. Prior to shipment to the clinic, in vitro
cohorts of Vascugel sponges were assayed for cell number,
viability, and secreted levels of HS and TGF-1. Each
sponge contained approximately 1.23  106 human aortic
EC (90% viability) secreting levels of 0.69  0.05 g/
mL/d HS and 566  29 pg/mL/d TGF- 1. Placebo
sponges were packaged identically and were of the same
shape and size, but lacked EC.
Study procedures. Study patients underwent planned
creation of surgical AV access using standard surgical and
anesthetic techniques per practice of the local treating
physicians. Sponges were placed at the conclusion of theprocedure after all bleeding at the sites has been controlled
and immediately before surgical closure. For all patients,
implant administration consisted of two sponges placed
adjacent to the venous anastomosis and outflow vein. Phase
II AVG patients received a third sponge adjacent to the
arterial anastomosis, for a total of three implanted sponges.
Patients received implant application at the time of access
placement and no repeat applications occurred during this
study. All phase II study patients, investigators, and other
members of the study team were blinded to treatment
assignment. The use of medications such as antibiotics,
heparin, and antithrombotics was at the discretion of the
treating physician and not specified in the protocol.
Following surgery, patients were seen and examined at
2, 4, 12, and 24 weeks to evaluate healing, access related
complications, adverse reactions, hospitalizations, patency,
and maturation. PRA were measured from serum samples
obtained at screening, 2, 4, 12, and 24 weeks. Serum
samples were screened for PRA using the LABScreen (One
Lambda, Inc, Canoga Park, Calif) Luminex platform. The
LABScreen Luminex method detects human leukocyte an-
tigen (HLA) antibodies using flow cytometric technology.
A number of exploratory analyses were also performed to
evaluate vein remodeling in AVF by color-flow duplex
ultrasound at 2, 4, 12, and 24 weeks and lumen diameter in
AVG and AVF by protocol-mandated angiography at 12
and 24 weeks for AVG and 24 weeks for AVF (Appendix,
online only). After the 24-week evaluation, patients were
offered the option of entering an extension study, where
safety and efficacy will continue to be assessed every 24
weeks for approximately 2.5 years (144 weeks).
Safety monitoring and study outcomes. The pri-
mary outcome of the trial was safety, assessed by the inci-
dence of infection (local or systemic), need for revision, and
development of thrombosis within 30 days after surgery.
The medical monitor was responsible for reviewing the
safety data for each patient enrolled in the study on an
ongoing basis, and a Pharmacovigilance group (Appendix,
online only) forwarded all serious adverse event (SAE)
reports to the DMC. Secondary outcomes were loss of
primary and assisted primary patency.26 In an attempt to
focus the patency analysis to within the treatment zone,
“anastomotic patency” was assessed by a blinded adjudica-
tion committee (Appendix, online only), which consisted
of an interventional radiologist, a vascular surgeon, and a
nephrologist. This committee used operative notes, radiol-
ogy reports, and primary review of angiograms to deter-
mine if an access failure could be specifically determined to
be related or unrelated to the treated anastomotic zone. If
the occlusion or causative lesion was determined to be in
the treatment area, or if no clear evidence existed to assign
a culprit lesion, then the determination was made that an
event occurred. If a specific causative lesion could be as-
signed outside of the treatment zone, then the determina-
tion was that an event did not occur. Additional secondary
outcomes were measurements of immunological sensitiza-
tion, defined as an increase in HLA antibodies using PRA
testing after surgery30% compared with screening levels;
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access placement to the first successful hemodialysis use.
Statistical methods. The primary and secondary safety
outcome analyses were performed on all enrolled patients
(safety population). The secondary efficacy outcome anal-
yses were performed on the intent-to-treat population
(ITT), which included all randomized patients who were
confirmed to have received Vascugel or placebo, excluding
the four AVG patients enrolled in the phase I portion of the
study because they received a different dose of product.
Secondary efficacy outcomes were also analyzed for the
modified intent-to-treat population (mITT), which was
prespecified in the protocol and defined in accordance with
The National Kidney Foundation Kidney Disease Out-
comes Quality Initiative (KDOQI) guidelines as the subset
of ITT patients who had successful hemodialysis initiation
within the first 2 months of creation of the AVG or within
the first 3 months of creation of the AVF. The primary
endpoint of infection (local wound or systemic), need for
revision, and development of thrombosis within 30 days,
the secondary efficacy endpoint of positive lumen diameter
changes at the anastomotic sites for graft patients, and the
Fig 2. Phase I and phase II combined participant flow
performed on 19 Vascugel patients in the ITT group and
and eight in the mITT group. Two of the 23 Vascugel (8
for dialysis during the 24-week follow-up period. Second
on 23 Vascugel patients in the ITT group and 12 in the
in the mITT group. Three of the 23 Vascugel (13%) an
dialysis during the 24-week follow-up period.secondary safety endpoint of PRA30% , were analyzed asdiscrete outcomes. The two treatment groups were com-
pared using Fisher exact test. The secondary safety end-
point (PRA) and the angiogram change analyses at each
location compared the two treatment groups using a Wil-
coxon rank sum test.
Secondary endpoint patency rates were described in a
continuous fashion, from the day of access placement until
the day of intervention or abandonment (an event) or the
subject’s last day on study (censored). Overall duration of
patency was analyzed using the Kaplan-Meier product limit
method. Results were summarized descriptively usingQ25,
median (95%CI), andQ75. Time to first use was calculated
as the time from the access placement to the first successful
hemodialysis use and analyzed in the same fashion as for
patency durations. For all secondary time-to-event end-
points inferential comparisons were made using the log-
rank statistic.
RESULTS
Patient population. A total of 109 patients were
screened with eight enrolled in the phase I portion of the
study and 57 randomized, 38 to receive Vascugel and 19 to
ondary outcome analysis for the AVG population was
the mITT group; 11 placebo patients in the ITT group
and two of the 11 placebo (18%) AVG were never used
utcome analysis for the AVF population was performed
group; eight placebo patients in the ITT group and six
of the eight placebo (12.5%) AVF were never used for. Sec
14 in
.7%)
ary o
mITT
d onereceive placebo (Fig 2), in the phase II portion of the study.
andard
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similar (Table I). Perioperative antibiotics were given in
52.2% of Vascugel patients and in 52.6% of placebo pa-
tients. Heparin was administered during the surgical pro-
cedure in 36.9% of Vascugel patients and in 26.3% of
placebo patients. The number of patients who died, were
lost to follow-up, or withdrew consent during the course of
the trial was eight (17.4%) in the Vascugel group and two
(10.5%) in the placebo group. The target of 2:1 random-
ization was achieved in the AVG group with a total of 23
patients in the Vascugel group and 11 patients in the
placebo group. Randomization in the AVF group was 3:1
with 23 patients in the Vascugel group and eight patients in
the placebo group. The imbalance in randomization be-
tween study arms occurred secondary to several patients
undergoing AVG placement based on intraoperative find-
ings, after having been initially assigned to the planned AVF
group.
Primary safety outcome. Comparison of the Vascu-
gel group and the placebo group in the safety population as
well as in each AVG and AVF safety subpopulation showed
no statistical difference between the two groups in the
incidence of local wound infection, access intervention or
the incidence of acute thrombosis within 30 days postsur-
gery (Table II). The Vascugel group demonstrated an
excellent safety profile. Separate analysis of wound infec-
tion, access intervention and incidence of acute thrombosis
Table I. Baseline characteristics of the participantsa
Characteristic
Va
N
Age, years 59.9
Male, %
Black, %
Cardiovascular disease, % 1
Diabetes mellitus, %
Body mass index, (kg/m2) 29.7
Systolic blood pressure (mm Hg) 145.2
Diastolic blood pressure (mm Hg) 79.2
Prior AV access in index armb
Prior AVG (%) 4
Prior AVF (%) 12
No prior access 7
Antithrombotic use, %
Antiplatelet use, %
Anticoagulant use, %
Statin use, %
Hemoglobin, g/dL 12.7
% Panel reactive antibodies 1.6
Hemodialysis initiated before study access creation, % 1
Study accessc
Forearm, % 1
Upper arm, % 22
AVG, Arteriovenous graft; AVF, arteriovenous fistulae.
aNo statistically significant differences observed in baseline characteristics b
bOne Vascugel AVF subject had two previous accesses, one AVG and one A
cStudy patients underwent planned creation of surgical AVG or AVF per stin the AVG ITT population that received three Vascugelsponges showed no increase in early complications at 4
weeks due to the addition of the third sponge (10.5% for
Vascugel vs 36.4% for placebo). A summary of adverse
events by system organ class is presented in Table III. The
majority of these events were unrelated to treatment as
determined by the investigator at each site; 8.7% of Vascu-
gel patients and 26.3% of placebo patients experienced
events that were considered possibly related. Events con-
sidered possibly related in the placebo group included
cellulitis, AVG thrombosis, and venous stenosis. Events
considered possibly related in the Vascugel group included
AVG thrombosis and venous stenosis. None of the events
was considered probably or definitely related.
SAEs were recorded from the time of consent for all
patients enrolled in the study who received Vascugel or
placebo. The majority of events were expected as typical
comorbidities in the ESRD patient population. The major-
ity of these events were unrelated to treatment as deter-
mined by the investigator at each site as well as the study
medical monitor; 4.3% patients in the Vascugel group and
none of the patients in the placebo group experienced
events that were considered possibly related. Events con-
sidered possibly related were AVG thrombosis. Overall, 38
patients (58% of the patients enrolled) reported a total of 73
SAEs. There was no statistically significant difference be-
tween groups in the number of SAEs reported.
Secondary efficacy outcomes - AVG cohort. Treatment
AVG AVF
l Placebo Vascugel Placebo
N  11 N  23 N  8
5.7 59.5  19.2 53.2  17.9 57.8  18.1
63.6 56.5 62.5
72.7 34.8 25.0
100 100 100
63.6 52.2 50
.9 27.9  4.2 26.3  6.7 28.7  4.1
7.4 143.5  36.7 127.8  21.2 144.4  24.5
1.1 78.8  19.2 76.6  14.2 76.9  18.1
) 0 1 (4.3) 0
) 5 (45.5) 5 (21.7) 1 (12.5)
6 (55) 18 (78) 7 (88)
81.8 78.3 62.5
63.6 60.9 62.5
45.5 52.2 50.0
36.4 56.5 37.5
.1 12.2  2.5 13.3  1.9 13.9  1.7
.2 4.0  7.3 0.43  1.2 0.88  2.5
100 100 100
1 (9.1) 2 (8.7) 1 (12.5)
) 10 (90.9) 21 (91.3) 7 (87.5)
groups.
practice and guidelines of the local treating physicians.scuge
 23
 1
52.2
73.9
00
69.5
 7
 2
 1
(17.4
(52.2
(30)
91.3
73.9
47.8
39.1
 2
 4
00
(4.3)
(95.7
etween
VF.with Vascugel did not significantly prolong unassisted or
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ITT ormITT populations (Fig 3). At 24 weeks, the primary
patency rate for ITT patients who received Vascugel was
38% vs 23% for placebo. Similarly, primary patency in the
mITT group was 49% vs 25% for Vascugel and placebo,
respectively. Vascugel assisted primary patency rates were
72% for ITT and 78% for mITT, vs 58% and 50%, respec-
tively, for the placebo group. Adjudication of graft events
to determine anastomotic patency did not result in signifi-
cant differences in patency rates (data not shown), due to
the difficulty in determining the presence and/or location
of the causative lesion in the grafts, especially after inter-
ventional procedures performed to treat thrombosed
grafts. There was no statistically significant difference in
time to first AVG use between the Vascugel and placebo
groups.
Quantitative angiography data (methods in Appendix,
online only) showed no significant differences between
Table II. Primary endpoint summary at 30 days: Safety po
Assessment
V
N
Local wound infection,a access intervention or Thrombosisb 5
● Local wound infectionf 2
● Access interventionf 2
● Thrombosisf 2
AVG, Arteriovenous graft; AVF, arteriovenous fistulae.
aLocal infection was defined as wound dehiscence with access exposure; graf
or cultures; or as four of the five following criteria: (1) need for intravenou
significant erythema, or (5) wound dehiscence without access exposure.
bTotal number of subjects who experienced any event (%).
cP  .430.
dP  .178.
eP  .999.
fIndividual subjects who experienced the specific event (%).
Table III. Adverse event by system organ class
System organ class
Vascugela Placeboa
n  46 n  19
Blood and lymphatic system disorders 4 (8.7%) 2 (10.5%)
Cardiac disorders 9 (19.6%) 4 (21.1%)
Gastrointestinal disorders 13 (28.3%) 5 (26.3%)
General disorders/administration site
conditions 14 (30.4%) 7 (36.8%)
Infections (systemic and access) 18 (39.1%) 9 (47.4%)
Procedural and access complications 20 (43.5%) 8 (42.1%)
Abnormal lab values 3 (6.5%) 2 (10.5%)
Musculoskeletal/connective tissue
disorders 7 (15.2%) 3 (15.8%)
Nervous system disorders 5 (10.9%) 2 (10.5%)
Renal and urinary disorders 2 (4.3%) 0
Respiratory and thoracic disorders 9 (19.6%) 3 (15.8%)
Skin and subcutaneous tissue
disorders 9 (19.6%) 2 (10.5%)
Vascular disorders 16 (34.8%) 9 (47.4%)
aNumber of subjects (%).groups in lumen diameter changes from 12-24 weeks (datanot shown). There was no observable difference in minimal
lumen diameter (MLD).
Secondary efficacy outcomes - AVF cohort. Treatment
with Vascugel did not significantly prolong unassisted or
assisted primary fistula patency compared with placebo in
the ITT or mITT populations (Fig 4). At 24 weeks, the
primary patency rates for ITT patients who received Vascu-
gel were 60% vs 62% for placebo. Primary patency in the
mITT group was 75% vs 65%, for Vascugel and placebo,
respectively. Assisted primary patency rates for ITT were
96% vs 88% for Vascugel and placebo, respectively. Assisted
primary patency in the mITT population was 100% in both
treatment groups. Blinded adjudication of fistula events
was more straightforward and resulted in a primary anasto-
motic patency in the ITT Vascugel group of 73% at 24
weeks compared with 58% in the placebo group and 92% vs
64% for Vascugel vs placebo in the mITT group (Fig 4).
Decisions to adjudicate an event as unrelated to the anas-
tomotic treatment area included cases of angioplasty of
central venous stenosis outside of the treatment area and
ligation of collateral venous branches without stenosis.
There was no statistically significant difference in time to
first AVF use between the Vascugel and placebo groups.
Angiography was performed only at 24 weeks in AVF
patients and analysis showed no significant differences be-
tween groups (data not shown). By ultrasound, positive
changes in venous lumen diameter were observed over time
in both groups (5.57  1.64 mm and 5.71  1.11 mm at
2 weeks, 5.93 1.89 mm and 5.31 1.24 mm at 4 weeks,
6.92 2.47 mm and 5.86 1.92 mm at 12 weeks, 7.01
2.66 mm and 7.41  2.844 mm at 24 weeks for Vascugel
and placebo, respectively).
Secondary safety outcome. A secondary safety end-
point of the study was to measure the development of PRA
over time. PRA testing determines the presence of anti-
HLA antibodies in serum samples and is reported as a
percentage. No statistically significant increases were ob-
tion
ty Population AVG AVF
el Placebo Vascugel Placebo Vascugel Placebo
6 N  19 N  23 N  11 N  23 N  8
%)c 4 (21.1%) 3 (13%)d 4 (36.4%) 2 (8.7%)e 0
) 2 (10.5%) 1 (4.3%) 2 (18.2%) 1 (4.3%) 0
) 1 (5.3%) 1 (4.3%) 1 (9.1%) 1 (4.3%) 0
) 2 (10.5%) 2 (8.7%) 2 (18.2%) 0 0
val for confirmed graft infection; purulent drainage with positive gram stain
iotics, (2) fever (100.5), (3) increased WBC count (12,000/L), (4)pula
Safe
ascug
 4
(10.9
(4.3%
(4.3%
(4.3%
t remo
s antibserved in class II anti-HLA antibodies (data not shown). At
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patency; B, mITT primary patency; C, ITT assisted primary patency; D, mITT assisted primary patency. Comparison
of the two treatment groups was made using the log-rank test.Fig 4. AVF secondary outcome of patency analyzed using the Kaplan Meier product limit method. A, ITT primary
patency; B, ITT primary anastomotic patency; C, mITT primary patency; D, mITT primary anastomotic patency.
Comparison of the two treatment groups was made using the log-rank test.
and a
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class I antibodies compared with Vascugel patients (P 
.005, Fig 5). No statistically significant differences were
observed at any of the other time points or in AVF patients.
An increase 30% compared with baseline levels in class I
anti-HLA antibodies was observed in four Vascugel AVG
patients, in one placebo AVG subject, and in five AVF
Vascugel patients and none of the placebo AVF patients
(P  .26, Fig 5). In all of the Vascugel patients who
experienced PRA elevations, one or more of the antibodies
were specific to the donor EC HLA antigens. Statistical
analysis revealed no relationship between an increase in
PRA and either access patency or the incidence of adverse
events at 24 weeks. Larger trials and longer time points are
needed to confirm this observation.
DISCUSSION
The V-HEALTH trial represents the first use of a novel
allogeneic endothelial implant in AV access patients. The
primary outcome of the trial, safety, was met. There was no
difference in the incidence of early complications for the
Vascugel group compared with placebo. There was no
evidence of local or systemic safety concerns for the Vascu-
Fig 5. Bar graph of increase in % PRA at 2, 4, 12, and
elevation in class I anti-HLA antibodies compared with
observed at any of the other time points. B, Time cour
08-009, 09-003, and 09-009) and one AVG placebo sub
for 02-016 and therefore the complete time course could
observed between AVF placebo and Vascugel patients at
Vascugel patients. Increases of PRA30% in either AVG
two treatment groups were compared (P  .26). The p
using the LABScreen Luminex platform which utilizes a
or class II HLA antigens and preoptimized reagents for th
and the LABScan 100 flow analyzer for data acquisitiongel group based on analysis of reported adverse events andSAEs. The adverse events observed were expected as typical
vascular access related complications or comorbidities asso-
ciated with the ESRD patient population. The present
study was not powered to detect efficacy of Vascugel, and
thus, larger trials will be necessary to detect statistical
differences in patency between treatment groups. A subset
of V-HEALTH patients entered into an extension study
where patency and access survival will continue to be as-
sessed. Results from the extension study will be the subject
of a follow-up report. The results of the present study
support further clinical investigation of Vascugel in the
setting of dialysis access surgery to explore efficacy, optimal
treatment dose, and potential consequences of repeat ad-
ministration.
A major challenge in caring for patients undergoing
hemodialysis for kidney failure is maintaining a functioning
vascular access. The current therapy for a failing vascular
access is either surgical revision or percutaneous interven-
tions.27 Although the exact causes of AVF and AVG steno-
sis and thrombosis are not completely understood, they are
likely encompassed within the paradigm of the vessel wall
injury response. Loss of endothelial integrity followed by
platelet activation, inflammation, and the migration and
eks. A, At 2 weeks, more AVG placebo patients had an
gel patients. No statistically significant differences were
PRA response in four AVG Vascugel patients (02-016,
2-011). Only baseline and 12-week PRA were obtained
e assessed.C,No statistically significant differences were
the time points.D, Time course of PRA response in five
F patients did not reach statistical significance when the
e of HLA antibodies in serum samples was determined
of color-coded micro-beads coated with purified class I
ection of class I or class II HLA antibodies in human sera
nalysis.24 we
Vascu
se of
ject (0
not b
any of
or AV
resenc
panel
e detproliferation of fibroblasts and SMC characterize this gen-
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stresses also occur as a result of the high-flow environment.
Preclinical studies have shown that when placed outside a
blood vessel, at the adventitia, EC decrease thrombosis,
stenosis and negative remodeling21,28 and provide the sci-
entific basis for the clinical development of Vascugel as a
locally applied perivascular therapy to improve healing at
sites of vascular interventions. Both Vascugel and Gelfoam
degrade in vivo between 4 to 6 weeks, however, animal data
have demonstrated beneficial effects of the perivascular EC
several months after degradation.23,29
The use of allogeneic EC has multiple benefits on the
manufacturing process, product release and quality assur-
ance. The use of qualified cell banks from single donors is
amenable to strict viral as well as functional testing prior to
formulation of the final product. Patients with cardiovascu-
lar disease and diabetes (100% and 59% of the V-HEALTH
population, respectively) are thought to have dysfunctional
endothelium and circulating auto-antibodies making use of
autologous EC from these patients less desirable.30-33
However, the use of allogeneic EC in patients that may
undergo kidney transplant required that we monitor for
immunosensitization. An elevation in PRA over the course
of the study, defined as a 30% increase over baseline, was
observed in 19.5% of the Vascugel group (9/46) and in
5.2% of the placebo group (1/19). The majority of eleva-
tions observed in the Vascugel patients were class I and
donor specific. There was no relationship between the
presence of PRA, access patency, or adverse events. Outside
of the context of this trial, sensitization is not an uncom-
mon clinical finding. Sensitization occurs in most people
through exposure to a foreign alloantigen, which can occur
through pregnancy, blood transfusions or prior transplan-
tation of solid organs or bone marrow.34-36 The implica-
tions of PRA increases or sensitization for potential kidney
transplant candidates are twofold: an increase in time
on the transplant wait list until a suitable donor is found37
and if transplanted, an increase in risk of antibody mediated
rejection may occur,38,39 which can be ameliorated with
programs such as paired kidney exchange, immunosuppres-
sion, or desensitization protocols.40 The V-HEALTH
study was conducted in dialysis patients who were not
under consideration for transplantation at the time of en-
rollment and therefore the results of transplantation in
V-HEALTH patients are unknown at this time. Additional
PRA data will continue to be collected in the extension
study.
The present study had several limitations. It was de-
signed as a small safety and feasibility study of a novel
cellular implant and therefore, not powered to detect ther-
apeutic benefit. The treatment of both AVG and AVF
allowed for patients to be enrolled and not lost due to last
minute decisions made concerning the type of access and
for safety to be assessed in both AVF and AVG. However,
this approach made efficacy analysis more difficult. In addi-
tion, a number of interventions that affected AVG primary
patency were triggered by the 12-week protocol-mandated
angiogram (30% of the Vascugel and 12% of the placebogroup). This observation is reflected in 24-week AVG
primary patency rates in the control group that are some-
what lower than those reported in the literature.41,42 De-
sign of future trials in which patency is a primary endpoint
should not specify an angiogram unless indicated by clinical
events. Targeted local therapy with tissue engineered en-
dothelial cell implants is a novel therapeutic approach that
is safe and may be ideally suited to control the response to
injury and inhibit clinical vascular dysfunction. Larger,
randomized trials will need to be performed to determine if
there is a benefit of Vascugel on AV access patency, matu-
ration and survival.
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METHODS
Ultrasound and Angiography Lumen Diameter
Measurements All lumen diameter measurements were
performed by a blinded interventional radiologist provided
by a core Imaging Lab (RadPharm). Venous lumen diam-
eters for AVF patients were obtained by US at 1 cm, 3 cm
and 5 cm from the venous anastomosis. Diameters at each
location were averaged to obtain one venous measurement
per patient at each time point. Venous and arterial lumen
diameters were obtained by angiography at the anastomosis
and up to 5 cm from the anastomosis at 0.5 cm increments.
Graft lumen diameters were obtained up to 5 cm into the
graft from either the venous or arterial anastomosis in 0.5
cm increments. Minimum lumen diameter was calculated
for each patient by taking the smallest measured diameter
over the 5 cm length of vessel. The frequency of positive
venous diameter changes was determined by determining
the distribution of patients with either positive or negative
changes at each of the distances measured (ie, at the anas-
tomosis, at the 10 distances measured between 0.5 and 5.0
cm into the venous outflow segment).
